Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Chiesi Farmaceutici S.p.A. clinical trials
Part of Valline S.r.l., which holds 76% as of 2026-05-13. Source
The registry lists 299 studies whose lead sponsor is Chiesi Farmaceutici S.p.A. or one of 23 companies grouped under it. 39 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 26, 2026.
Keep track of what changes. Save the Chiesi Farmaceutici S.p.A. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Chiesi Farmaceutici S.p.A..
- Chiesi Farmaceutici S.p.A.185 studiesSame company
Something wrong?
- ApoPharma23 studies →Acquired
Something wrong?
- Aegerion Pharmaceuticals, Inc.17 studies →Acquired — became part of Chiesi Farmaceutici S.p.A., Apr 12, 2023 · source ↗
Something wrong?
- KalVista Pharmaceuticals, Ltd.15 studies →Acquired — became part of Chiesi Farmaceutici S.p.A., Jun 11, 2026 · source ↗
Something wrong?
- Zymenex A/S8 studies →Acquired
Something wrong?
- Birken AG6 studies →Acquired — became part of Chiesi Farmaceutici S.p.A., Apr 12, 2023 · source ↗
Something wrong?
- Amryt Pharma5 studies →Acquired — became part of Chiesi Farmaceutici S.p.A., Apr 12, 2023 · source ↗
Something wrong?
- Critical Therapeutics5 studies →Acquired — became part of Chiesi Farmaceutici S.p.A., Jul 28, 2009 · source ↗
Something wrong?
- Chiesi Italia5 studies →Regional office
Something wrong?
- Chiesi UK4 studies →Regional office
Something wrong?
- Chiesi Hungary Ltd.4 studies →Regional office
Something wrong?
- Atopix Therapeutics, Ltd.3 studies →Acquired
Something wrong?
- Chiesi Poland Sp. z o.o.3 studies →Regional office
Something wrong?
- Chiesi SAS3 studies →Acquired — became part of Chiesi Farmaceutici S.p.A., Jul 28, 2009 · source ↗
Something wrong?
- Chiasma, Inc.3 studies →Acquired — became part of Chiesi Farmaceutici S.p.A., Apr 12, 2023 · source ↗
Something wrong?
- Chiesi Canada Corp2 studies →Regional office
Something wrong?
- Chiesi Bulgaria1 study →Regional office
Something wrong?
- Cornerstone Therapeutics Inc.1 study →Acquired — became part of Chiesi Farmaceutici S.p.A., Jul 28, 2009 · source ↗
Something wrong?
- Chiesi Slovenija, d.o.o.1 study →Regional office
Something wrong?
- Amryt Research Limited1 study →Acquired — became part of Chiesi Farmaceutici S.p.A., Apr 12, 2023 · source ↗
Something wrong?
- EKR Therapeutics, Inc1 study →Acquired — became part of Chiesi Farmaceutici S.p.A., Jun 26, 2012 · source ↗
Something wrong?
- Chiesi USA, Inc.1 study →Acquired — became part of Chiesi Farmaceutici S.p.A., Jul 28, 2009 · source ↗
Something wrong?
- Chiesi Pharma AB, Nordic1 study →Subsidiary
Something wrong?
- Chiesi Farmaceutica Ltda.1 study →Regional office
Something wrong?
Focus areas
Conditions Chiesi Farmaceutici S.p.A. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 299. Browse all 299 →
- PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI)RecruitingNCT05652439
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Doses of Inhaled CHF10073 in Participants With Idiopathic Pulmonary FibrosisNot yet recruitingNCT07876284Phase 1
- A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary FibrosisRecruitingNCT07516951Phase 2
- Evaluation of Safety, Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body in Healthy Adults and Adults With AsthmaRecruitingNCT07851623Phase 1
- Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With AsthmaNot yet recruitingNCT07858123Phase 3
- A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving FilsuvezRecruitingNCT06423573
- Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)RecruitingNCT07654829Phase 4
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted after KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
- Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and Removed in Healthy SubjectsRecruitingNCT07163182Phase 1
- A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseaseRecruitingNCT06328608Phase 2/3
- A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower CholesterolNot yet recruitingNCT07744386Phase 1
- BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])RecruitingNCT07666490Phase 4
- Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With SebetralstatAvailableNCT07216378
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
- MEASuRE: Metreleptin Effectiveness And Safety RegistryRecruitingNCT02325674
- Open-label Extension Study to Evaluate Metreleptin in Patients With Partial LipodystrophyRecruitingNCT06679270Phase 3
- Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world SettingRecruitingNCT07109375
Sponsor listed in the registry: Chiesi Italia
- Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonistsRecruitingNCT07546981Phase 3
- A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male ParticipantsNot yet recruitingNCT07683793Phase 1
- Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate AsthmaRecruitingNCT07301736Phase 2
- A Study to Evaluate the Efficacy and Safety of CHF10196 Tablets (Florensocatib) Compared With Placebo in Male and Female Participants 12 to 85 Years of Age With BronchiectasisNot yet recruitingNCT07577804Phase 3
- Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD PatientsRecruitingNCT07406048
Sponsor listed in the registry: Chiesi Farmaceutica Ltda.
- Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant PatientsRecruitingNCT06833463
Sponsor listed in the registry: Chiesi Poland Sp. z o.o.
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)RecruitingNCT07489911
Sponsor listed in the registry: Chiesi Slovenija, d.o.o.
- Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and BreastfeedingRecruitingNCT06941025
- Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry DiseaseRecruitingNCT05710692Phase 2/3
- A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis BullosaRecruitingNCT06917690Phase 3
- A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry PatientsRecruitingNCT06663358
- Efficacy of a Smart add-on Device in Combination With a Triple Treatment in Asthma Patients on Inhaler Technique and AdherenceRecruitingNCT06908421
Sponsor listed in the registry: Chiesi Pharma AB, Nordic
- Bedside Ultrasound to Monitor Lung Function and Blood Flow in Newborns Treated With SurfactantNot yet recruitingNCT07070167
Sponsor listed in the registry: Chiesi Poland Sp. z o.o.
- Open-label Study to Evaluate Metreleptin in Patients With Partial LipodystrophyRecruitingNCT06484868Phase 4
Sponsor listed in the registry: Amryt Pharma · First submitted after Amryt Pharma became part of Chiesi Farmaceutici S.p.A.
- Utilising Hull Lung Health Study Data to Investigate the Performance of TidalSense Diagnostic Algorithms to Identify COPD and Pre-COPD Among Participants in the FRONTIER Programme.Not yet recruitingNCT06788613
Sponsor listed in the registry: Chiesi UK
- Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3RecruitingNCT06184503
- Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial IntelligenceNot yet recruitingNCT06960824
Sponsor listed in the registry: Chiesi SAS · First submitted after Chiesi SAS became part of Chiesi Farmaceutici S.p.A.
- The Importance of Tailored Education And Device Handling for Asthmatic PatientsNot yet recruitingNCT06840522
Sponsor listed in the registry: Chiesi Hungary Ltd.
- Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life SettingRecruitingNCT06678191
Sponsor listed in the registry: Chiesi Hungary Ltd.
- TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma PatientsRecruitingNCT06567977
Sponsor listed in the registry: Chiesi Poland Sp. z o.o.
- Assessment of the Pharmacokinetic Profile of Tacrolimus Medications and Their Relation to Effectiveness and Safety in Liver Transplant PatientsRecruitingNCT05744635
Sponsor listed in the registry: Chiesi Hungary Ltd.
- Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT StudyRecruitingNCT05948891
Sponsor listed in the registry: Chiesi SAS · First submitted after Chiesi SAS became part of Chiesi Farmaceutici S.p.A.
- Expanded Access to Velmanase AlfaAvailableNCT04959240
- A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related OutcomesRecruitingNCT05728749
Sponsor listed in the registry: Chiesi SAS · First submitted after Chiesi SAS became part of Chiesi Farmaceutici S.p.A.
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With BronchiectasisCompletedNCT06166056Phase 1/2
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPDCompletedNCT04320342Phase 3
- Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma ControlCompletedNCT05168995
Sponsor listed in the registry: Chiesi Italia
- Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).CompletedNCT06264674Phase 3
- AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)CompletedNCT02123667
- ARCANGELO (itAlian pRospective Study on CANGrELOr)CompletedNCT04471870
- Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world SettingCompletedNCT06100042
Sponsor listed in the registry: Chiesi Italia
- Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.CompletedNCT03453112Phase 3
- A Study in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01245569Phase 3
- Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or IICompletedNCT06467084Phase 3
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
- Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised LipodystrophyTerminatedNCT06502990Phase 3
Sponsor listed in the registry: Amryt Pharma · First submitted after Amryt Pharma became part of Chiesi Farmaceutici S.p.A.